{"id":151854,"date":"2022-12-04T19:24:28","date_gmt":"2022-12-05T01:24:28","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/12\/hiv-vaccine-trial-makes-pivotal-leap-toward-making-super-antibodies"},"modified":"2022-12-04T19:24:28","modified_gmt":"2022-12-05T01:24:28","slug":"hiv-vaccine-trial-makes-pivotal-leap-toward-making-super-antibodies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/12\/hiv-vaccine-trial-makes-pivotal-leap-toward-making-super-antibodies","title":{"rendered":"HIV Vaccine Trial Makes Pivotal Leap Toward Making \u2018Super Antibodies\u2019"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/hiv-vaccine-trial-makes-pivotal-leap-toward-making-super-antibodies2.jpg\"><\/a><\/p>\n<p>The announcement comes from the journal <i>Science<\/i>, which published Phase 1 results of a small clinical trial for a vaccine technology that aims to cause the body to create a rare kind of cell.<\/p>\n<p>\u201cAt the most general level, the trial results show that one can design vaccines that induce antibodies with pre-specified genetic features, and this may herald a new era of precision vaccines,\u201d William Schief, PhD, a researcher at The Scripps Research Institute and study co-author, told the American Association for the Advancement of <i>Science<\/i> (AAAS).<\/p>\n<p>The study was the first to test the approach in humans and was effective in 97% \u2013 or 35 of 36 \u2013 participants. The vaccine technology is called \u201cgermline targeting.\u201d Trial results show that \u201cone can design a vaccine that elicits made-to-order antibodies in humans,\u201d Schief said in a <a href=\"https:\/\/www.scripps.edu\/news-and-events\/press-room\/2022\/20221202-schief-hiv.html\"> news release<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The announcement comes from the journal Science, which published Phase 1 results of a small clinical trial for a vaccine technology that aims to cause the body to create a rare kind of cell. \u201cAt the most general level, the trial results show that one can design vaccines that induce antibodies with pre-specified genetic features, [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-151854","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/151854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=151854"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/151854\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=151854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=151854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=151854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}